Andreas Rummel

USPTO Granted Patents = 12 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 1.5

ph-index = 7

Forward Citations = 102(Granted Patents)

Location History:

Garbsen, DE (2012)
Hanover, DE (2015 - 2019)
Hannover, DE (2013 - 2022)

Company Filing History:

8 out of 27

Ipsen Bioinnovation Limited

Years Active: 2012-2022

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11441141 - Methods for the manufacture of proteolytically processed polypeptides (2022-09-13),

2. 10883096 - Carrier for targeting nerve cells (2021-01-05),

3. 10808236 - Methods for the manufacture of proteolytically processed polypeptides (2020-10-20),

4. 10266816 - Carrier for targeting nerve cells (2019-04-23),

5. 10087432 - Methods for the manufacture of proteolytically processed polypeptides (2018-10-02),

6. 9650622 - Carrier for targeting nerve cells (2017-05-16),

7. 9422344 - Transport protein which is used to introduce chemical compounds into nerve cells (2016-08-23),

8. 9234011 - Transport protein which is used to introduce chemical compounds into nerve cells (2016-01-12),

9. 9115350 - Carrier for targeting nerve cells (2015-08-25),

10. 8481040 - Carrier for targeting nerve cells (2013-07-09),

11. 8476024 - Botulinum neurotoxin a protein receptor and uses thereof (2013-07-02),

12. 8293230 - Transport protein which is used to introduce chemical compounds into nerve cells (2012-10-23),

Title: Innovations and Contributions of Inventor Andreas Rummel

Introduction

Andreas Rummel is a notable inventor based in Hannover, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of polypeptides and neurotoxin modifications. With a total of 12 patents to his name, Rummel's work has implications in both pharmaceutical and cosmetic applications.

Latest Patents

Rummel's latest patents include innovative methods for the manufacture of proteolytically processed polypeptides. One of his patents describes a proteolytically active polypeptide that comprises an acid sequence with at least 50% sequence identity to a specified sequence, while ensuring that it does not include the exact amino acid sequence of that reference. Additionally, he has developed a transport protein that targets nerve cells, which can be modified to alter its affinity and neurotoxicity compared to the native neurotoxin. This invention also encompasses methods for producing the protein and its applications in various compositions.

Career Highlights

Throughout his career, Rummel has worked with prominent companies such as Ipsen Bioinnovation Limited and Toxogen GmbH. His experience in these organizations has allowed him to refine his expertise in biotechnology and contribute to groundbreaking research and development.

Collaborations

Rummel has collaborated with notable professionals in his field, including Tanja Weil and Aleksandrs Gutcaits. These partnerships have further enhanced his research capabilities and innovation potential.

Conclusion

Andreas Rummel's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the industry. His work continues to influence advancements in medical and cosmetic applications.

This text is generated by artificial intelligence and may not be accurate.